Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour intraocular pressure lowering effect of omidenepag isopropyl
jRCTs031200106Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of omidenepag isopropyl in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoints: Change in diurnal mean intraocular pressure from baseline to Week 4 and Change in nocturnal mean intraocular pressure from baseline to Week 4. Started Sep 2020; status: completed.
02
Drugs
omidenepag isopropyl
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCTs031200106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200106.